Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4906 AL 4920

The biomarker and therapeutic potential of miRNA in Alzheimer's disease

Bekris LM, Leverenz JB.

Neurodegener Dis Manag. 2015;5(1):61-74. doi: 10.2217/nmt.14.52.

What lessons can be learned from failed Alzheimer's disease trials?

Toyn J.

Expert Rev Clin Pharmacol. 2015 May;8(3):267-9. doi: 10.1586/17512433.2015.1034690. Epub 2015 Apr 10.

Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease

Li Y, Wang J, Zhang S, Liu Z.

J Neurosci Res. 2015 Sep;93(9):1325-9. doi: 10.1002/jnr.23564. Epub 2015 Jun 11.

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R.

Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.

Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment

Nordberg A, Kadir A, Andreasen N, Almkvist O, Wall A, Långström B, Zetterberg H.

J Alzheimers Dis. 2015;47(3):691-704. doi: 10.3233/JAD-132474.

Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications

Jha NK, Jha SK, Kumar D, Kejriwal N, Sharma R, Ambasta RK, Kumar P.

J Alzheimers Dis. 2015;48(4):891-917. doi: 10.3233/JAD-150379.

Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease

Rommer PS, Fuchs D, Leblhuber F, Schroth R, Greilberger M, Tafeit E, Greilberger J.

Neurodegener Dis. 2016;16(3-4):284-9. doi: 10.1159/000441565. Epub 2015 Nov 21.

Facilitating the use of implicit memory and learning in the physical therapy management of individuals with Alzheimer disease: a case series

White L, Ford MP, Brown CJ, Peel C, Triebel KL.

J Geriatr Phys Ther. 2014 Jan-Mar;37(1):35-44. doi: 10.1519/JPT.0b013e3182862d2c.

Curcumin and curcumin-like molecules: from spice to drugs

Marchiani A, Rozzo C, Fadda A, Delogu G, Ruzza P.

Curr Med Chem. 2014;21(2):204-22. doi: 10.2174/092986732102131206115810.

Disruption of zinc neuromodulation by Aß oligomers: therapeutic implications

Vogler EC, Busciglio J.

Curr Pharm Des. 2014;20(15):2520-4. doi: 10.2174/13816128113199990510.

Hippocampal neurogenesis in Alzheimer's disease: is there a role for dietary modulation?

Maruszak A, Pilarski A, Murphy T, Branch N, Thuret S.

J Alzheimers Dis. 2014;38(1):11-38. doi: 10.3233/JAD-131004.

Cellular prion protein as a therapeutic target in Alzheimer's disease

Laurén J.

J Alzheimers Dis. 2014;38(2):227-44. doi: 10.3233/JAD-130950.

Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination

van Wijk N, Broersen LM, de Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, Kamphuis PJ.

J Alzheimers Dis. 2014;38(3):459-79. doi: 10.3233/JAD-130998.

Current view from Alzheimer disease to type 2 diabetes mellitus

Rasool M, Malik A, Qazi AM, Sheikh IA, Manan A, Shaheen S, Qazi MH, Chaudhary AG, Abuzenadah AM, Asif M, Alqahtani MH, Iqbal Z, Shaik MM, Gan SH, Kamal MA.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):533-42. doi: 10.2174/18715273113126660167.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias